JPS56135419A - Preventive and improver for radiation disorder - Google Patents
Preventive and improver for radiation disorderInfo
- Publication number
- JPS56135419A JPS56135419A JP3823580A JP3823580A JPS56135419A JP S56135419 A JPS56135419 A JP S56135419A JP 3823580 A JP3823580 A JP 3823580A JP 3823580 A JP3823580 A JP 3823580A JP S56135419 A JPS56135419 A JP S56135419A
- Authority
- JP
- Japan
- Prior art keywords
- bacterium
- oligosaccharides
- improver
- preventive
- gal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
PURPOSE: A preventive and improver for disorders occurring during irradiation for remedying malignant tumor, etc., comprising a bacterium belonging to the genus bifidobacterium and factors for promoting its propagation as active ingredients.
CONSTITUTION: The titled preventive and improver comprising a bacterium belonging to the genus Bifidobacterium [e.g., bifidobacterium (a bacterium derived from babies of human breast milk nutrition), Lactobacillus acidophilus (derived from human and bacterium occurring fixedly in mouse)], a kind of bacterium existing always in the intestines, and oligosaccharides (namely, oligosaccharides obtained by treating lactose with β-glactosidase, usually a mixture of oligosaccharides) shown by the formula Gal-(Gal)m-Glc(Gal is galactose residue; Glc is glucose residue; n is 1-4) as active ingredients. When the bacterium of the genus Bifidobacterium is blended with the abovementioned oligosaccharides, factors for promoting its propagation and it is propagated specifically in the intestines, disorders caused by irradiation to digestive tubes for remedying malignant tumor, etc. are prevented and improved.
COPYRIGHT: (C)1981,JPO&Japio
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3823580A JPS56135419A (en) | 1980-03-27 | 1980-03-27 | Preventive and improver for radiation disorder |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3823580A JPS56135419A (en) | 1980-03-27 | 1980-03-27 | Preventive and improver for radiation disorder |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS56135419A true JPS56135419A (en) | 1981-10-22 |
JPS6241569B2 JPS6241569B2 (en) | 1987-09-03 |
Family
ID=12519630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP3823580A Granted JPS56135419A (en) | 1980-03-27 | 1980-03-27 | Preventive and improver for radiation disorder |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS56135419A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100330054A1 (en) * | 2007-10-11 | 2010-12-30 | Fayrefield Foods Limited | Preparation, use of preparation for treatment, and method of treatment of intestinal infection |
-
1980
- 1980-03-27 JP JP3823580A patent/JPS56135419A/en active Granted
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100330054A1 (en) * | 2007-10-11 | 2010-12-30 | Fayrefield Foods Limited | Preparation, use of preparation for treatment, and method of treatment of intestinal infection |
Also Published As
Publication number | Publication date |
---|---|
JPS6241569B2 (en) | 1987-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Riggio et al. | Effect of lactitol and lactulose administration on the fecal flora in cirrhotic patients | |
Terada et al. | Effect of lactulose on the composition and metabolic activity of the human faecal flora | |
CA2099855C (en) | Antigastritis agent | |
Sanders | Lactic acid bacteria as promoters of human health | |
Bolognani et al. | Influence of carcinogen binding by lactic acid-producing bacteria on tissue distribution and in vivo mutagenicity of dietary carcinogens | |
Kolida et al. | Prebiotic effects of inulin and oligofructose | |
TWI491732B (en) | Equol-containing fermented soybean hypocotyl and method of producing the same | |
Bolognani et al. | Effect of lactobacilli, bifidobacteria and inulin on the formation of aberrant crypt foci in rats | |
EP1112692B1 (en) | Drinks and foods capable of eliminating helicobacter pylori | |
Voorhess et al. | URINARY EXCRETION OF NOREPINEPHRINE, EPINEPHRINE AND 3-METHOXY-4-HYDROXYMANDELIC ACID BY CHILDREN WITH NEURO-BLASTOMA | |
Taper et al. | Possible adjuvant cancer therapy by two prebiotics-inulin or oligofructose | |
Cole et al. | Effect of probiotic supplements of lactobacillus acidophilus and Bifidobacterium adolescentis 2204 on β-glueosidase and β-glueuronidase activity in the lower gut of rats associated with a human faecal flora | |
BRPI0206689B1 (en) | composition of probiotics and use of this | |
Yamazaki et al. | The effect of an oral administration of Lactobacillus casei strain shirota on azoxymethane-induced colonic aberrant crypt foci and colon cancer in the rat. | |
Parodi | The role of intestinal bacteria in the causation and prevention of cancer: modulation by diet and probiotics | |
PT1649760E (en) | Composition containing lactic acid bacterium producing equol | |
Adachi | Lactic acid bacteria and the control of tumours | |
WO1999017788A1 (en) | Composition of treatment of candidiasis | |
Shen et al. | Immunomopharmacological effects of polysaccharides from Acanthopanax senticosus on experimental animals | |
Apgar et al. | The effect of feeding various levels of Bifidobacterium globosum A on the performance, gastrointestinal measurements, and immunity of weanling pigs and on the performance and carcass measurements of growing-finishing pigs | |
Herich et al. | The effect of Lactobacillus paracasei and Raftilose P95 upon the non-specific immune response of piglets | |
JPS56135419A (en) | Preventive and improver for radiation disorder | |
WO2002045727A1 (en) | Lactic acid bacteria inhibiting adhesion of helicobacter pylori to gastric mucosa | |
Vanderhoof et al. | The role of probiotics in the treatment of intestinal infections and inflammation | |
Visek | Dietary protein and experimental carcinogenesis |